{"ABBV": {"Ticker": "ABBV", "Company": "AbbVie", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$192"}, {"Date": "2022-02-28", "Rating": "Downgrade", "Organization": "UBS", "Rating_Change": "Buy to Neutral", "Target_Change": "$129 to $147"}, {"Date": "2022-02-03", "Rating": "Reiterated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$117 to $122"}, {"Date": "2022-02-03", "Rating": "Reiterated", "Organization": "BofA Securities", "Rating_Change": "Neutral", "Target_Change": "$135 to $138"}, {"Date": "2022-02-03", "Rating": "Reiterated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$153 to $154"}, {"Date": "2022-02-03", "Rating": "Reiterated", "Organization": "Barclays", "Rating_Change": "Equal Weight", "Target_Change": "$133 to $150"}, {"Date": "2022-01-13", "Rating": "Initiated", "Organization": "Redburn", "Rating_Change": "Buy", "Target_Change": ""}, {"Date": "2022-01-12", "Rating": "Reiterated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$134 to $153"}], "Score": 0.88, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 8, "Period": "180 days", "Analists": ["UBS", "BMO Capital Markets", "Goldman", "Morgan Stanley", "Redburn", "BofA Securities", "Barclays"], "Price_Target": 131.0}, "ABMD": {"Ticker": "ABMD", "Company": "Abiomed", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform", "Target_Change": "$330"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Wolfe Research"], "Price_Target": 330.0}, "AMP": {"Ticker": "AMP", "Company": "Ameriprise Financial", "Sector": "Financials", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Neutral to Underweight", "Target_Change": "$325 to $310"}, {"Date": "2022-03-01", "Rating": "Downgrade", "Organization": "Piper Sandler", "Rating_Change": "Overweight to Neutral", "Target_Change": "$370 to $325"}, {"Date": "2022-01-26", "Rating": "Initiated", "Organization": "Jefferies", "Rating_Change": "Buy", "Target_Change": "$355"}], "Score": -0.33, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 3, "Period": "180 days", "Analists": ["Piper Sandler", "Jefferies"], "Price_Target": 330.0}, "APTV": {"Ticker": "APTV", "Company": "Aptiv", "Sector": "Consumer Discretionary", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Upgrade", "Organization": "BofA Securities", "Rating_Change": "Underperform to Buy", "Target_Change": "$125 to $165"}], "Score": 3.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["BofA Securities"], "Price_Target": 165.0}, "BMY": {"Ticker": "BMY", "Company": "Bristol Myers Squibb", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Underweight", "Target_Change": "$64"}], "Score": -1.0, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Morgan Stanley"], "Price_Target": 64.0}, "KMX": {"Ticker": "KMX", "Company": "CarMax", "Sector": "Consumer Discretionary", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$195 to $165"}, {"Date": "2022-02-16", "Rating": "Downgrade", "Organization": "Evercore ISI", "Rating_Change": "Outperform to In-line", "Target_Change": "$120"}, {"Date": "2022-01-28", "Rating": "Resumed", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$157 to $140"}, {"Date": "2022-01-27", "Rating": "Upgrade", "Organization": "Seaport Research Partners", "Rating_Change": "Neutral to Buy", "Target_Change": "$140"}], "Score": 0.25, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Analists": ["Seaport Research Partners", "Evercore ISI", "RBC Capital Mkts", "BofA Securities"], "Price_Target": 141.25}, "EW": {"Ticker": "EW", "Company": "Edwards Lifesciences", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$134"}, {"Date": "2022-03-16", "Rating": "Upgrade", "Organization": "Bernstein", "Rating_Change": "Mkt Perform to Outperform", "Target_Change": "$132 to $135"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Neutral", "Target_Change": "$130"}, {"Date": "2022-02-02", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$121 to $126"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Neutral", "Target_Change": "$125 to $121"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$132 to $120"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$134 to $126"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Evercore ISI", "Rating_Change": "Outperform", "Target_Change": "$130 to $122"}, {"Date": "2022-01-27", "Rating": "Reiterated", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$142 to $138"}], "Score": 1.56, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 9, "Period": "180 days", "Analists": ["UBS", "Wolfe Research", "BofA Securities", "Raymond James", "Citigroup", "Stifel", "Bernstein", "Evercore ISI"], "Price_Target": 128.0}, "EA": {"Ticker": "EA", "Company": "Electronic Arts", "Sector": "Communication Services", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$166"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Wells Fargo", "Rating_Change": "Equal Weight", "Target_Change": "$175 to $155"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$185 to $158"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "MKM Partners", "Rating_Change": "Buy", "Target_Change": "$172 to $162"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Deutsche Bank", "Rating_Change": "Buy", "Target_Change": "$175 to $170"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Barclays", "Rating_Change": "Equal Weight", "Target_Change": "$152 to $127"}, {"Date": "2022-01-19", "Rating": "Upgrade", "Organization": "Atlantic Equities", "Rating_Change": "Neutral to Overweight", "Target_Change": "$160"}], "Score": 1.43, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 7, "Period": "180 days", "Analists": ["MKM Partners", "Wells Fargo", "Atlantic Equities", "BofA Securities", "Raymond James", "Barclays", "Deutsche Bank"], "Price_Target": 156.86}, "LLY": {"Ticker": "LLY", "Company": "Eli Lilly & Co", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$265 to $364"}, {"Date": "2022-03-10", "Rating": "Initiated", "Organization": "Daiwa Securities", "Rating_Change": "Outperform", "Target_Change": "$286"}, {"Date": "2022-01-21", "Rating": "Upgrade", "Organization": "DZ Bank", "Rating_Change": "Hold to Buy", "Target_Change": "$291"}], "Score": 1.67, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 3, "Period": "180 days", "Analists": ["Morgan Stanley", "DZ Bank", "Daiwa Securities"], "Price_Target": 313.67}, "FIS": {"Ticker": "FIS", "Company": "Fidelity National Information Services", "Sector": "Information Technology", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Stephens", "Rating_Change": "Overweight", "Target_Change": "$125"}, {"Date": "2022-04-05", "Rating": "Initiated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$132"}, {"Date": "2022-02-16", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$134 to $113"}, {"Date": "2022-02-16", "Rating": "Reiterated", "Organization": "Jefferies", "Rating_Change": "Buy", "Target_Change": "$135 to $120"}, {"Date": "2022-02-16", "Rating": "Reiterated", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": "$140 to $135"}, {"Date": "2022-01-10", "Rating": "Upgrade", "Organization": "Exane BNP Paribas", "Rating_Change": "Neutral to Outperform", "Target_Change": "$138"}], "Score": 1.67, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 6, "Period": "180 days", "Analists": ["Wells Fargo", "Exane BNP Paribas", "Morgan Stanley", "Jefferies", "Stephens", "Credit Suisse"], "Price_Target": 127.17}, "FISV": {"Ticker": "FISV", "Company": "Fiserv", "Sector": "Information Technology", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Stephens", "Rating_Change": "Equal-Weight", "Target_Change": "$110"}, {"Date": "2022-04-05", "Rating": "Initiated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$122"}, {"Date": "2022-01-14", "Rating": "Downgrade", "Organization": "KeyBanc Capital Markets", "Rating_Change": "Overweight to Sector Weight", "Target_Change": ""}, {"Date": "2022-01-12", "Rating": "Downgrade", "Organization": "Jefferies", "Rating_Change": "Buy to Hold", "Target_Change": "$120 to $115"}], "Score": -0.25, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 4, "Period": "180 days", "Analists": ["Wells Fargo", "Jefferies", "Stephens", "KeyBanc Capital Markets"], "Price_Target": 85.75}, "GPN": {"Ticker": "GPN", "Company": "Global Payments", "Sector": "Information Technology", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Stephens", "Rating_Change": "Overweight", "Target_Change": "$170"}, {"Date": "2022-04-05", "Rating": "Initiated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$194"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Analists": ["Wells Fargo", "Stephens"], "Price_Target": 182.0}, "IR": {"Ticker": "IR", "Company": "Ingersoll Rand", "Sector": "Industrials", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Downgrade", "Organization": "Wolfe Research", "Rating_Change": "Outperform to Peer Perform", "Target_Change": ""}], "Score": -2.0, "Cumulative_Rating": "Significant Underperform", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Wolfe Research"], "Price_Target": -1.0}, "ISRG": {"Ticker": "ISRG", "Company": "Intuitive Surgical", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform", "Target_Change": "$315"}, {"Date": "2022-03-25", "Rating": "Initiated", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$340"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$340"}, {"Date": "2022-02-02", "Rating": "Upgrade", "Organization": "UBS", "Rating_Change": "Neutral to Buy", "Target_Change": "$317 to $325"}, {"Date": "2022-01-31", "Rating": "Upgrade", "Organization": "Piper Sandler", "Rating_Change": "Neutral to Overweight", "Target_Change": "$300 to $310"}, {"Date": "2022-01-25", "Rating": "Downgrade", "Organization": "Redburn", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2022-01-21", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": "$370 to $360"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$381 to $350"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Neutral", "Target_Change": "$338 to $317"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$370 to $325"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Robert W. Baird", "Rating_Change": "Outperform", "Target_Change": "$370 to $315"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Raymond James", "Rating_Change": "Outperform", "Target_Change": "$383 to $334"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Piper Sandler", "Rating_Change": "Neutral", "Target_Change": "$330 to $300"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$375 to $325"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Evercore ISI", "Rating_Change": "In-line", "Target_Change": "$340 to $290"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "Deutsche Bank", "Rating_Change": "Hold", "Target_Change": "$323 to $300"}, {"Date": "2022-01-21", "Rating": "Reiterated", "Organization": "BTIG Research", "Rating_Change": "Buy", "Target_Change": "$372 to $360"}, {"Date": "2022-01-10", "Rating": "Upgrade", "Organization": "BTIG Research", "Rating_Change": "Neutral to Buy", "Target_Change": "$372"}], "Score": 1.17, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 18, "Period": "180 days", "Analists": ["UBS", "Wolfe Research", "Wells Fargo", "Morgan Stanley", "Redburn", "Robert W. Baird", "BofA Securities", "Citigroup", "Raymond James", "RBC Capital Mkts", "Stifel", "BTIG Research", "Deutsche Bank", "Piper Sandler", "Evercore ISI"], "Price_Target": 308.89}, "JNJ": {"Ticker": "JNJ", "Company": "Johnson & Johnson", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$173"}, {"Date": "2022-03-16", "Rating": "Downgrade", "Organization": "Bernstein", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$180 to $183"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Neutral", "Target_Change": "$185"}], "Score": -0.67, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 3, "Period": "180 days", "Analists": ["Morgan Stanley", "BofA Securities", "Bernstein"], "Price_Target": 180.33}, "MKTX": {"Ticker": "MKTX", "Company": "MarketAxess", "Sector": "Financials", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Downgrade", "Organization": "Raymond James", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": ""}, {"Date": "2022-02-15", "Rating": "Initiated", "Organization": "Credit Suisse", "Rating_Change": "Neutral", "Target_Change": "$412"}, {"Date": "2022-02-08", "Rating": "Initiated", "Organization": "Atlantic Equities", "Rating_Change": "Neutral", "Target_Change": "$380"}, {"Date": "2022-01-27", "Rating": "Downgrade", "Organization": "Compass Point", "Rating_Change": "Neutral to Sell", "Target_Change": "$300"}], "Score": -0.75, "Cumulative_Rating": "Underperform", "Number_of_Analysts": 4, "Period": "180 days", "Analists": ["Credit Suisse", "Raymond James", "Compass Point", "Atlantic Equities"], "Price_Target": 272.0}, "MRK": {"Ticker": "MRK", "Company": "Merck & Co.", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$80"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Morgan Stanley"], "Price_Target": 80.0}, "OXY": {"Ticker": "OXY", "Company": "Occidental Petroleum", "Sector": "Energy", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Stifel", "Rating_Change": "Buy", "Target_Change": "$84"}, {"Date": "2022-03-14", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Overweight to Equal-Weight", "Target_Change": "$52"}, {"Date": "2022-03-08", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$65 to $80"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 3, "Period": "180 days", "Analists": ["Morgan Stanley", "Stifel", "BofA Securities"], "Price_Target": 72.0}, "OGN": {"Ticker": "OGN", "Company": "Organon & Co.", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$35"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Morgan Stanley"], "Price_Target": 35.0}, "PYPL": {"Ticker": "PYPL", "Company": "PayPal", "Sector": "Information Technology", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Stephens", "Rating_Change": "Equal-Weight", "Target_Change": "$135"}, {"Date": "2022-04-05", "Rating": "Initiated", "Organization": "Wells Fargo", "Rating_Change": "Overweight", "Target_Change": "$152"}, {"Date": "2022-03-30", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Buy", "Target_Change": "$144"}, {"Date": "2022-03-09", "Rating": "Downgrade", "Organization": "BofA Securities", "Rating_Change": "Buy to Neutral", "Target_Change": "$175 to $107"}, {"Date": "2022-02-03", "Rating": "Downgrade", "Organization": "DZ Bank", "Rating_Change": "Buy to Hold", "Target_Change": "$140"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$230 to $160"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": "$263 to $218"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Truist", "Rating_Change": "Hold", "Target_Change": "$200 to $130"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Susquehanna", "Rating_Change": "Positive", "Target_Change": "$310 to $220"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$230 to $180"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Piper Sandler", "Rating_Change": "Overweight", "Target_Change": "$280 to $185"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$217 to $190"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "KeyBanc Capital Markets", "Rating_Change": "Overweight", "Target_Change": "$250 to $200"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "JP Morgan", "Rating_Change": "Overweight", "Target_Change": "$272 to $190"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "JMP Securities", "Rating_Change": "Mkt Outperform", "Target_Change": "$260 to $198"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Evercore ISI", "Rating_Change": "Outperform", "Target_Change": "$342 to $245"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Deutsche Bank", "Rating_Change": "Buy", "Target_Change": "$260 to $200"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": "$250 to $190"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Cowen", "Rating_Change": "Outperform", "Target_Change": "$221 to $147"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$224 to $180"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Atlantic Equities", "Rating_Change": "Overweight", "Target_Change": "$280 to $180"}, {"Date": "2022-02-02", "Rating": "Downgrade", "Organization": "Raymond James", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": ""}, {"Date": "2022-02-02", "Rating": "Downgrade", "Organization": "BTIG Research", "Rating_Change": "Buy to Neutral", "Target_Change": ""}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Wedbush", "Rating_Change": "Outperform", "Target_Change": "$220 to $170"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Jefferies", "Rating_Change": "Hold", "Target_Change": "$200 to $145"}, {"Date": "2022-02-02", "Rating": "Reiterated", "Organization": "Canaccord Genuity", "Rating_Change": "Buy", "Target_Change": "$315 to $215"}, {"Date": "2022-01-26", "Rating": "Reiterated", "Organization": "BTIG Research", "Rating_Change": "Buy", "Target_Change": "$345 to $270"}, {"Date": "2022-01-12", "Rating": "Downgrade", "Organization": "Jefferies", "Rating_Change": "Buy to Hold", "Target_Change": "$255 to $200"}, {"Date": "2022-01-10", "Rating": "Downgrade", "Organization": "Exane BNP Paribas", "Rating_Change": "Outperform to Neutral", "Target_Change": "$200"}], "Score": 1.07, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 29, "Period": "180 days", "Analists": ["Wolfe Research", "UBS", "Canaccord Genuity", "Deutsche Bank", "BTIG Research", "JMP Securities", "BMO Capital Markets", "Morgan Stanley", "Jefferies", "Cowen", "DZ Bank", "RBC Capital Mkts", "JP Morgan", "Exane BNP Paribas", "KeyBanc Capital Markets", "Atlantic Equities", "BofA Securities", "Wedbush", "Truist", "Wells Fargo", "Goldman", "Stephens", "Susquehanna", "Credit Suisse", "Raymond James", "Piper Sandler", "Evercore ISI"], "Price_Target": 166.66}, "PFE": {"Ticker": "PFE", "Company": "Pfizer", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "Morgan Stanley", "Rating_Change": "Equal-Weight", "Target_Change": "$55"}], "Score": 0.0, "Cumulative_Rating": "Neutral", "Number_of_Analysts": 1, "Period": "180 days", "Analists": ["Morgan Stanley"], "Price_Target": 55.0}, "RMD": {"Ticker": "RMD", "Company": "ResMed", "Sector": "Health Care", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$280"}, {"Date": "2022-01-31", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2022-01-31", "Rating": "Upgrade", "Organization": "Citigroup", "Rating_Change": "Neutral to Buy", "Target_Change": ""}, {"Date": "2022-01-28", "Rating": "Upgrade", "Organization": "RBC Capital Mkts", "Rating_Change": "Underperform to Sector Perform", "Target_Change": "$234 to $241"}, {"Date": "2022-01-24", "Rating": "Upgrade", "Organization": "BofA Securities", "Rating_Change": "Underperform to Neutral", "Target_Change": "$239 to $250"}, {"Date": "2022-01-24", "Rating": "Upgrade", "Organization": "JP Morgan", "Rating_Change": "Neutral to Overweight", "Target_Change": ""}, {"Date": "2022-01-13", "Rating": "Upgrade", "Organization": "Robert W. Baird", "Rating_Change": "Neutral to Outperform", "Target_Change": "$270 to $300"}, {"Date": "2022-01-13", "Rating": "Upgrade", "Organization": "CLSA", "Rating_Change": "Outperform to Buy", "Target_Change": ""}], "Score": 1.62, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 8, "Period": "180 days", "Analists": ["CLSA", "Wolfe Research", "JP Morgan", "Goldman", "Robert W. Baird", "BofA Securities", "Citigroup", "RBC Capital Mkts"], "Price_Target": 129.88}, "SYF": {"Ticker": "SYF", "Company": "Synchrony Financial", "Sector": "Financials", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Upgrade", "Organization": "Piper Sandler", "Rating_Change": "Neutral to Overweight", "Target_Change": "$48 to $49"}, {"Date": "2022-03-28", "Rating": "Downgrade", "Organization": "Morgan Stanley", "Rating_Change": "Overweight to Equal-Weight", "Target_Change": "$56 to $40"}, {"Date": "2022-03-17", "Rating": "Downgrade", "Organization": "Wolfe Research", "Rating_Change": "Outperform to Peer Perform", "Target_Change": ""}, {"Date": "2022-01-31", "Rating": "Reiterated", "Organization": "Stephens", "Rating_Change": "Equal-Weight", "Target_Change": "$58 to $54"}, {"Date": "2022-01-31", "Rating": "Reiterated", "Organization": "Seaport Research Partners", "Rating_Change": "Buy", "Target_Change": "$60 to $54"}, {"Date": "2022-01-31", "Rating": "Reiterated", "Organization": "Piper Sandler", "Rating_Change": "Neutral", "Target_Change": "$52 to $48"}, {"Date": "2022-01-31", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$66 to $56"}, {"Date": "2022-01-31", "Rating": "Reiterated", "Organization": "Credit Suisse", "Rating_Change": "Outperform", "Target_Change": "$60 to $58"}, {"Date": "2022-01-31", "Rating": "Reiterated", "Organization": "BMO Capital Markets", "Rating_Change": "Outperform", "Target_Change": "$54 to $50"}], "Score": 0.78, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 9, "Period": "180 days", "Analists": ["Wolfe Research", "BMO Capital Markets", "Morgan Stanley", "Stephens", "Seaport Research Partners", "Credit Suisse", "Piper Sandler"], "Price_Target": 44.44}, "TTWO": {"Ticker": "TTWO", "Company": "Take-Two Interactive", "Sector": "Communication Services", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$213"}, {"Date": "2022-03-04", "Rating": "Upgrade", "Organization": "MKM Partners", "Rating_Change": "Neutral to Buy", "Target_Change": "$200"}, {"Date": "2022-01-19", "Rating": "Upgrade", "Organization": "Exane BNP Paribas", "Rating_Change": "Neutral to Outperform", "Target_Change": "$180 to $215"}, {"Date": "2022-01-12", "Rating": "Upgrade", "Organization": "BMO Capital Markets", "Rating_Change": "Market Perform to Outperform", "Target_Change": "$180"}, {"Date": "2022-01-11", "Rating": "Downgrade", "Organization": "MoffettNathanson", "Rating_Change": "Buy to Neutral", "Target_Change": "$170"}], "Score": 1.4, "Cumulative_Rating": "Outperform", "Number_of_Analysts": 5, "Period": "180 days", "Analists": ["MKM Partners", "BMO Capital Markets", "Exane BNP Paribas", "BofA Securities", "MoffettNathanson"], "Price_Target": 195.6}, "GWW": {"Ticker": "GWW", "Company": "W. W. Grainger", "Sector": "Industrials", "Updated": "2022-04-06", "Rating": [{"Date": "2022-04-06", "Rating": "Upgrade", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform to Outperform", "Target_Change": ""}, {"Date": "2022-03-15", "Rating": "Upgrade", "Organization": "Atlantic Equities", "Rating_Change": "Neutral to Overweight", "Target_Change": "$580"}], "Score": 2.0, "Cumulative_Rating": "Significant Outperform", "Number_of_Analysts": 2, "Period": "180 days", "Analists": ["Atlantic Equities", "Wolfe Research"], "Price_Target": 289.0}}